Iterum Therapeutics 

Iterum Therapeutics plc, an Irish pharmaceutical company founded in Dublin in 2015, is dedicated to the development and commercialization of treatments for bacterial infections that are resistant to existing drugs. Operating in Ireland, Bermuda, and the United States, the firm currently markets ORLYNVAH, an oral penem antibiotic. This medication is prescribed for adult women experiencing uncomplicated urinary tract infections (uUTIs) caused by specific microorganisms such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, particularly when alternative oral antibacterial treatments are limited or unavailable. Furthermore, Iterum is actively progressing sulopenem, an innovative anti-infective compound. This drug, being developed in both oral and intravenous formulations, is intended to address a range of conditions, including uncomplicated and complicated urinary tract infections, complicated intra-abdominal infections, community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. The company is currently in a state of reorganization.